Effectiveness and safety of adefovir dipivoxil combined with bicyclol in treatment of chronic hepatitis B
CHENG Wei-ni
XU Yuan
CHENG Li-xin
LU Ning
Abstract：Objective To analyze the efficacy and safety of adefovir dipivoxil combined with bicyclol in treatment of chronic hepatitis B (CHB). Methods A total of 87 patients with CHB were randomized into experimental group(44 cases) and control group(43 cases). The patients in the experimental group received adefovir dipivoxil orally 10 mg daily and bicyclol orally 75 mg daily for 48 weeks and control group received adefovir dipivoxil orally 10 mg daily alone for 48 weeks. The live function(serum transaminase ect), HBV DNA, and HBeAg/antiHBe were observed before and after treatment. Results Compared with pre-treatment, the live function decreased obviously in two groups respectively, especially in the experimental group [ALT: (40.3 ± 16.5)U/L vs (46.7 ±13.1)U/L, AST: (37.5 ±19.4)U/L vs (45.4 ±26. 1)U/L, A/G:(1.4 ±0.2) vs (1.3 ±0.3), r-GT:(35.8 ±21.4)U/L vs (55.2 ± 17.3)U/L, TBIL: (14.8 ± 12.3) μmol/L vs (16.8 ± 11.7) μmol/L, P ＜0.05, P＜0. 01)]. HBV DNA negative conversion rate also decreased (P ＜ 0.01), while the comparison between the two group after the treatment was not significantly different. There were no statistical differences between the two groups or per-treatment and treatment regarding with HBeAg seroconversion rate. Conclusion Administration of adefovir dipivoxil combined with bicyclol is effective and safe in the treatment of CHB, especially in HBV DNA negative conversion and the live function.
Keywords：Hepatitis BchronicAdefovir dipivoxilBicyclol
Publication Date：2011-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)